DESCRIPTIONRimonabant is a selective antagonist of cannabinoid-1 receptors, part of the endocannabinoid system that regulates energy balance, glucose and lipid metabolism and body weight, and modulates the intake of highly palatable, sweet or fatty foods. In clinical trials, one year's treatment with rimonabant 20 mg/day in conjunction with diet and exercise significantly reduced body weight compared with placebo. In patients with high blood pressure or dyslipidemia this was associated with improvements in lipid levels (but not LDL-cholesterol), fasting glucose and insulin resistance, and in patients with type 2 diabetes inadequately controlled with metformin or sulfonylurea, treatment with rimonabant was associated with improvements in HbA-1C.
ORIGINAL USES (ON-LABEL)
Treatment of obesity and overweight in adults.
NEWLY DISCOVERED USES (OFF-LABEL)
Cocaine and tobacco addiction, cannabis abuse (blockade of cannabis effects), cardiovascular disease prevention.
POTENTIAL SIDE EFFECTS
Nausea, anxiety, depression, dizziness, diarrhoea and insomnia, upset stomach, muscle cramps or spasm, tendonitis, excessive sweating, nervousness, itching, bruising, memory loss, back pain, joint sprain.
CAUTIONS
- Use with caution in patients over 75 years of age.
- Tell your physician if you are currently being treated for epilepsy.
- This drug is not recommended for use in children below age 18.
- Tell your physician if you have severely impaired renal function or impaired liver function.
CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, telithromycin, clarithromycin, nefazodone). CYP3A4 inducers (rifampicin, phenytoin, phenobarbital, carbamazepine).
HERBAL INTERACTIONS
St John's wort
PREGNANCY AND BREAST-FEEDING CAUTIONS
This drug should not be taken during pregnancy. Do not take this medicine when breast-feeding.
SPECIAL INFORMATION
It is not known how rimonabant compares with established treatments for obesity and overweight. There is no data on maintenance of weight loss or cost effectiveness of this treatment. Lifestyle changes and more established drug treatments should remain preferred options before the use of rimonabant is considered.
HOW EFFECTIVE IS IT?
Acomplia has been assessed in three randomised placebo controlled trials in obese or overweight patients with dyslipidemia and/or hypertension (RIO-Europe, n=1507; RIO-Lipids, n=1036; and RIO-North America, n=3045). All patients were assigned a hypocaloric diet (daily deficit 600 kcal) and encouraged to exercise. Patients with diabetes, cardiovascular disease and psychiatric illness were excluded. The primary endpoint in each trial was the change from baseline in mean body weight after one year. In RIO-North America, patients who had been taking rimonabant were rerandomised after one year to continue Acomplia or switch to placebo for a further year. The trials assessed 5 and 20 mg/day doses of rimonabant; only data for the licensed dose are reported here. Data were analysed by carrying forward the last observations made; this may bias outcomes since most weight loss occurs in the first 9 months.
All the trials included a 4-week run-in period before randomization, during which the mean weight loss was 1.9 - 2 kg. Approximately 40% of patients in each trial, evenly divided between the groups, did not complete a year's treatment. The mean weight loss one year after randomization was between 6.3 and 8.6 kg with rimonabant vs. 1.5 and 2.3 kg with placebo (p<0.001). In RIO-North America, patients who continued to take Acomplia for a further year maintained their weight loss whereas those reassigned to placebo regained their lost weight.
In patients taking Acomplia, weight loss was ≥ 5% of baseline in 49 - 58% of patients compared with 19 - 20% with placebo (p<0.001). The corresponding figures for ≥ 10% weight loss were 25 - 33% vs. 7 - 9% respectively (p<0.001).
Weight loss was consistently associated with reductions in other risk factors, including waist circumference, triglyceride levels, fasting insulin and glucose levels and insulin resistance; HDL-cholesterol increased but there was no significant effect on LDL-cholesterol. Approximately 45 - 60% of the increase in HDL cholesterol and the reduction in triglyceride, and half of the reduction in insulin levels and insulin resistance, was attributable to weight loss, suggesting an additional direct effect of drug treatment. The prevalence of metabolic syndrome was reduced from 32 - 53% at baseline to 29 - 41% with placebo and 21 - 26% with Acomplia.
Acomplia has also been assessed in a randomised placebo controlled trial in overweight or obese patients with type 2 diabetes inadequately controlled with metformin or sulfonylurea (RIO-Diabetes, n=1,047). One year's treatment with rimonabant was associated with weight loss and improvements in lipid profiles similar to those reported in non-diabetic patients (5.3 kg for rimonabant vs. 1.4 kg for placebo, p<0.0001); in addition, HbA1C was reduced by 0.6% compared with an increase of 0.1% with placebo (p<0.0001).
HOW SAFE IS IT?
Overall more patients taking rimonabant discontinued treatment due to adverse events (13-15% vs. 5-9% with placebo). The adverse events reported more frequently with rimonabant were nausea (11-13% vs. 3-6%), dizziness (6-10% vs. 4-7%), anxiety (6-9% vs. 2-4%), diarrhoea (5-7% vs. 3-7%) and insomnia (6% vs. 3-4%). The incidence of depression was slightly greater, and more often led to discontinuation, with rimonabant than placebo. No clinically significant cardiovascular effects were reported.
WHEN SHOULD RIMONABANT BE USED?
We recommends drug treatment for up to a year for the majority of adults with obesity or who are overweight as part of a treatment strategy when diet, exercise and behavioural therapy have failed. It is not known how Acomplia compares with established treatments. Its role in patients with cardiovascular disease is currently uncertain; it has not been evaluated in children. More established drug treatments should remain preferred options before the use of rimonabant is considered.
Buy Acomplia online
Where can I buy Acomplia without prescription?Rimonabant is a prescription drug that comes in 20 mg tablets. It is available on prescription only as tablets for oral use, but the online pharmacy, will sell Rimonabant without prescription. You may be able to order Acomplia from them online and save the local pharmacy markup.
Whether I can pay my Rimonabant order by Credit Card?
Pharmacies accept credit cards Visa and Mastercard, online checks (ACH), EuroDebit, Wire transfers.
Is the Acomplia purchase legal?
Yes, it is legal. You confirm, that buy Acomplia tablets only for personal use without the purposes of resale. All medicines are solved for application in the majority of the countries. Generic Rimonabant should pass any customs house, including American, without problems. If you have problems with customs house, inform pharmacy, they shall repeat (free-of-charge) your Rimonabant order.
If I'm buying Acomplia online for the first time?
Buy Rimonabant online after comparing prices to your local pharmacy and you'll agree - any drugstore can sell you generic cheap Acomplia at a reduced cost.
PEOPLE WHO READ THIS ARTICLE ALSO READ ABOUT...
Xenical without prescription, Florinef online, Topamax order, Tadalafil online, Lasix order
WHERE CAN I... ?
Buy Meridia, Order Levitra, Buy Cipro
KNOW MORE ABOUT...
Alli pills, Cheap Viagra, Lorazepam online, Generic Valium
To browse our Alphabetic Index, click on a letter:
What is Rimonabant?
Acomplia is licensed as an adjunct to diet and exercise for the treatment of obese patients (body mass index, BMI, ≥30 kg/m2) or overweight patients (BMI ≥27 kg/m2) who have associated risk factors such as type 2 diabetes or dyslipidemia.
Acomplia is licensed as an adjunct to diet and exercise for the treatment of obese patients (body mass index, BMI, ≥30 kg/m2) or overweight patients (BMI ≥27 kg/m2) who have associated risk factors such as type 2 diabetes or dyslipidemia.
BRAND NAME
Zimulti, Acomplia
GENERIC NAME
Rimonabant
CHEMICAL CLASS
CB1 cannabinoid receptor antagonist
THERAPEUTIC CLASS
Weight loss
Zimulti, Acomplia
GENERIC NAME
Rimonabant
CHEMICAL CLASS
CB1 cannabinoid receptor antagonist
THERAPEUTIC CLASS
Weight loss
AVAIL FORMS
Tablets — Oral 20 mg, film-coated.
Tablets — Oral 20 mg, film-coated.
DOSAGE
Adult
PO 20 mg tablet daily to be taken in the morning before breakfast.
Adult
PO 20 mg tablet daily to be taken in the morning before breakfast.
Please enter a search term to begin your search.